Derivation Web

source_c35f23fb5e464981

by researka:v2 · 2026-06-22 18:18:33.636336+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
HbA 1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Real-World Use of GLP-1 Receptor Agonist Liraglutide in Adolescents with Obesity: A First Longitudinal Single-Center Analysis from Switzerland †,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
The multifaceted effects of semaglutide: exploring its broad therapeutic applications,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
12608 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Cost-effectiveness of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
GLP-1 receptor agonist–induced diabetic ketoacidosis: A case report,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"MON-701 A case which GLP 1 receptor agonist semaglutide enabled the management of both obesity and diabetes mellitus, suggesting the potential for diabetes remission",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"A Nationwide Danish Comparative Effectiveness Study of GLP‐1 RA, SGLT2i and DPP‐4i Treatment on Risk of Stroke, Myocardial Infarction and Mortality in Type 2 Diabetes",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Impact of GLP-1 Receptor Agonists and Dual/Triple Incretin Therapies on Cardiometabolic Outcomes Beyond Glycemic Control: Evidence from Recent Randomized Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Unmasking an insulinoma: recurrent Hypoglycemia in a young patient following GLP-1 receptor agonist therapy —A case report,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Integrating GLP-1 Receptor Agonists into Modern Stroke Prevention: Evidence, Mechanisms, and Clinical Consideration—A Narrative Review",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Employing an Artificial Intelligence Platform to Enhance Treatment Responses to GLP-1 Agonists by Utilizing Metabolic Variability Signatures Based on the Constrained Disorder Principle,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Addressing patient concerns about the ‘newness’ and long-term safety of GLP-1 receptor agonists: A clinician’s guide to counseling,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Potential application of mono-, dual-, and triple-target GLP-1 receptor agonists in improving the prognosis of patients with diabetic foot ulcers",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Randomisation to Endobarrier Alone 2017,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
PCOS 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Effect of Oral Semaglutide 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Effect of Semaglutide on Bone 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Studenski 2011,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
WHO 2000,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Cruz-Jentoft 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Ioannidis 2005,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "2b3d1eb0-8efe-4468-b234-8a534f83b06b",
  "researka_submission_id": "55294f57-700e-484d-8893-908a24c86e60",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/2b3d1eb0-8efe-4468-b234-8a534f83b06b/sidecars/evidence_table.csv"
}